We use cookies to provide a user-friendly experience. By continuing to browse this site you give consent for cookies to be used. To find out more or to set your own preferences please read our cookie policy.
Steven Bell looks at what the introduction of the new vaccine could mean for the economy.
How to embrace the opportunities that change creates
Macro Update 23 November 2020
David Sneyd is joined by Jo Raven from the FAIRR Initiative to discuss the progress that is already underway to create a more sustainable food production system, including the rise of alternative, plant-based proteins in the food supply chain.
The team at LGM provide their regular update on responsible investing in emerging markets.
Antimicrobial resistance is accelerating at a rate that could threaten modern medicine. Why is it a material issue for food companies?
Antimicrobial resistance threatens our entire healthcare ecosystem. Why is it a particularly pressing issue for pharmaceutical companies?
Discover how COVID-19 is impacting cybersecurity and data privacy
Macro Update 2 November 2020
Discover how COVID-19 has pushed AGMs around the world into an online format.
Explore the executive pay implications of COVID-19 at top UK companies
In this report, we carry out a deep dive into our engagement activities, showing the alignment to the SDGs and their targets.
While many balanced investors are understandably worried about low returns becoming the ‘new normal’, we believe that allocating smartly can more than offset the drag that structural challenges could exert on portfolios.
How is the pharmaceutical industry responding to COVID-19?
How did the global financial crisis shape investor engagement?
Discover investor engagement escalation strategies.
We consider what good investor engagement looks like.
